Related references
Note: Only part of the references are listed.
Article
Biochemistry & Molecular Biology
Hung Fu Tseng et al.
Summary: A test-negative case-control analysis using data from a diverse population in California, USA, demonstrates that vaccine efficacy of a three-dose regimen of the mRNA-1273 COVID-19 vaccine is reduced against infection with the Omicron SARS-CoV-2 variant in comparison to Delta, but that efficacy against hospitalization remained high for both variants.
Letter
Medicine, General & Internal
Shirley Collie et al.
Summary: Preliminary data from a test-negative study design in South Africa showed that two doses of the BNT162b2 vaccine had an efficacy of 50 to 70% against hospitalization caused by the omicron variant in Gauteng province.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Nick Andrews et al.
Summary: A study conducted in England showed that vaccines against SARS-CoV-2 provide high protection against hospitalization and death from Covid-19 at 20 weeks or more after vaccination. However, the effectiveness of the vaccines decreases over time, especially in individuals aged 65 and older and those with underlying risk factors.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Dan-Yu Lin et al.
Summary: In a study conducted in North Carolina, Covid-19 vaccines were found to be highly effective in preventing hospitalization and death for up to 9 months after vaccination. The decrease in protection against infection over time was attributed to both declining immunity and the emergence of the delta variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Eero Poukka et al.
Summary: Recently, the effectiveness of Covid-19 vaccines, especially against mild disease, has decreased due to the emergence of the Delta variant and waning protection. A register-based study in Finland found that the vaccine effectiveness of two-dose mRNA vaccine series against SARS-CoV-2 infection decreased from 82% to 53% after 6 months. Similar trends were observed for other vaccine series. Waning protection was not observed against Covid-19 hospitalization. These results inform decision-making regarding booster doses for healthcare workers.
Article
Public, Environmental & Occupational Health
Mark G. Thompson et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2022)
Article
Immunology
Danuta M. Skowronski et al.
Summary: Test-negative design studies conducted in British Columbia and Quebec, Canada, among adults show that 2 doses of homologous or heterologous SARS-CoV-2 vaccines provide substantial and sustained protection against hospitalization, supporting the use of mixed schedules and longer intervals between doses.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Infectious Diseases
Fredrik Kahn et al.
Summary: We compared the risk of severe COVID-19 between the periods of 2021 and 2022 in Scania county, Sweden, when Delta and Omicron were the dominant virus variants. Adjusting for factors like sex, age, comorbidities, prior infection, and vaccination, we found that the risk of severe disease from Omicron was significantly lower among vaccinated cases. It was also lower among the unvaccinated population, but remained high (> 5%) for older individuals and middle-aged men with multiple comorbidities. Efforts to increase vaccination uptake should continue.
Article
Immunology
Heini Salo et al.
Summary: This study aimed to investigate the impact of age and underlying medical conditions on the risk of severe outcomes following SARS-CoV-2 infection and how to prioritize vaccinations against COVID-19 accordingly. The results showed that age and various comorbidities were predictors of severe COVID-19. Vaccine prioritization should take into account both the risk of infection and the risk of severe outcomes if infected.
Article
Multidisciplinary Sciences
Hiam Chemaitelly et al.
Summary: mRNA COVID-19 vaccines provide moderate and short-lived protection against symptomatic Omicron BA.1 and BA.2 infections, but strong and durable protection against COVID-19 hospitalization and death.
NATURE COMMUNICATIONS
(2022)
Article
Multidisciplinary Sciences
Ludek Berec et al.
Summary: Studies in Czech Republic show that the effectiveness of COVID-19 vaccines declines after 7-8 months, with a decrease in protection against infection, hospitalization, and death. Boosters are found to restore the original vaccine effectiveness, and post-infection immunity also diminishes over time.
Article
Multidisciplinary Sciences
Ausenda Machado et al.
Summary: This study aimed to evaluate the COVID-19 vaccine effectiveness in individuals aged 65 and above. The results showed that the vaccines had good protection against symptomatic infection in the 65-79 age group, with an estimated VE of around 65%. The VE against COVID-19 hospitalization and death was also high, at around 95% and 81% respectively. However, in the 80 and above age group, there was a slight decrease in the effectiveness of the vaccines against symptomatic infection and COVID-19 hospitalization.
Article
Biochemistry & Molecular Biology
Rebecca P. Payne et al.
Summary: The study demonstrates that the first dose of the BNT162b2 mRNA vaccine can induce protection against the B.1.1.7 variant within weeks, and extending the interval between doses can result in higher levels of neutralizing antibody response. Prior infection with the virus can accelerate the immune response.
Article
Medicine, General & Internal
Sara Y. Tartof et al.
Summary: This study aimed to assess the overall and variant-specific effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19-related hospital admissions among members of a healthcare system in California. The effectiveness of the vaccine remained high against hospital admissions even up to 6 months after full vaccination, despite a decline in effectiveness against SARS-CoV-2 infections over time, which was likely due to waning immunity rather than the delta variant escaping vaccine protection.
Article
Medicine, General & Internal
Noam Barda et al.
Summary: A study using data from Israel's largest health-care organization showed that a third dose of the BNT162b2 mRNA vaccine is effective in preventing individuals from severe COVID-19-related outcomes, compared to receiving only two doses at least 5 months ago. The effectiveness of the third dose in preventing hospital admission was 93%, severe disease 92%, and COVID-19-related death 81%.
Article
Medicine, General & Internal
Yair Goldberg et al.
Summary: The immunity against the delta variant of SARS-CoV-2 waned in all age groups in Israel a few months after receiving the second dose of the vaccine, leading to an increase in infection and severe cases.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Yinon M. Bar-On et al.
Summary: The study shows that receiving a booster dose of the BNT162b2 vaccine can significantly lower the rates of confirmed Covid-19 and severe illness, as well as reduce mortality among individuals aged 60 and above.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Ulrike Baum et al.
Summary: An analysis conducted in Finland on elderly individuals and those with chronic illnesses showed that vaccines can provide protection against SARS-CoV-2 infection and Covid-19 hospitalization to a certain extent. Both mRNA and adenovirus vector vaccines demonstrated effectiveness, with higher protection observed after the second dose.
Article
Multidisciplinary Sciences
Gayatri Amirthalingam et al.
Summary: The UK extended the interval between COVID-19 vaccine doses to 12 weeks, leading to higher antibody levels and estimated greater vaccine effectiveness. This study highlights the importance of an extended vaccine schedule in enhancing protection against COVID-19.
NATURE COMMUNICATIONS
(2021)
Article
Infectious Diseases
Ulrike Baum et al.
Article
Medicine, General & Internal
H. M. El Sahly et al.
Summary: The mRNA-1273 vaccine demonstrated high efficacy in preventing COVID-19 illness and severe disease, with more than 5 months of protection and a good safety profile, including protection against asymptomatic infection.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
S. J. Thomas et al.
Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Health Care Sciences & Services
Peter Nordstrom et al.
Summary: The study suggests that heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and mRNA vaccines is an effective alternative to increase population immunity against Covid-19, with higher effectiveness compared to homologous vaccination. These findings could have significant implications for vaccination strategies and logistics in the battle against the Covid-19 pandemic.
LANCET REGIONAL HEALTH-EUROPE
(2021)
Article
Infectious Diseases
Angela Rose et al.
Review
Medicine, General & Internal
W. Joost Wiersinga et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2020)
